Pages Menu
FacebookTwitterPinterestRss
Categories Menu

Posted by on Apr 1, 2010 in Foundation NewsLine, Type C |

Health Canada Approves Zavesca for Use in Niemann-Pick Type C; First Authorized Treatment in Canada

Health Canada recently announced its approval of the drug Zavesca (miglustat) as the first authorized treatment for neurological symptoms of Niemann-Pick Disease Type C (NPC). Zavesca is not a cure for NPC, but it has shown promise in treating symptoms related to NPC and in slowing the progression of the disease for some patients.

For more details, click here.

Share this!

Please spread the word!

FACEBOOK
TWITTER
PINTEREST